Krystal Biotech vs Repligen
Add, change or remove companies; up to four.
KIRA’s take AI analyst
I put Krystal Biotech and Repligen side by side, using each one’s latest annual report. Here is what stands out:
- Repligen is the larger business, with $738M of revenue in fiscal 2025 against $389M for Krystal Biotech, about 1.9 times as much.
- Krystal Biotech grew revenue faster (33.9%, against 16.4%).
- Krystal Biotech kept more of each dollar of sales as operating profit (41.5% operating margin, against 7.5%).
- Krystal Biotech turned more of its sales into free cash flow (48.6% FCF margin, against 12.7%).
- Krystal Biotech earned a higher return on the capital invested in it (43.6%, against 2.4%).
Who comes out ahead
Of the 7 measures where higher (or lower) is clearly better, how many each company leads.
Krystal Biotech
KRYS
7/7
Revenue growthOperating marginNet marginFCF marginReturn on capitalReturn on equityNet debt / EBITDA
Repligen
RGEN
0/7
Side by side
Best in the row
| Latest fiscal year | KRYS FY25 | RGEN FY25 |
|---|---|---|
| Size | ||
| Market cap | $9.6B | — |
| Revenue | $389M | $738M |
| Free cash flow | $189M | $93.9M |
| Net income | $205M | $48.9M |
| Growth | ||
| Revenue growth | 33.9% | 16.4% |
| 5-year growth | — | 15.1% |
| Share count change | 0.7% | — |
| Profitability | ||
| Gross margin | — | 52.3% |
| Operating margin | 41.5% | 7.5% |
| Net margin | 52.6% | 6.6% |
| FCF margin | 48.6% | 12.7% |
| Return on capital | 43.6% | 2.4% |
| Return on equity | 18.9% | 2.4% |
| Balance sheet | ||
| Net debt | −$828M | −$225M |
| Net debt / EBITDA | −5.0x | −1.7x |
| Dividends and buybacks | $0.0M | $0.0M |
| Valuation & quality | ||
| P/E | 39.0x | — |
| Piotroski F-score | 5 | — |
Ten years
Revenue
FY16
KRYS —
RGEN $105M
FY17
KRYS —
RGEN $141M
FY18
KRYS —
RGEN $194M
FY19
KRYS —
RGEN $270M
FY20
KRYS —
RGEN $366M
FY21
KRYS $0.0M
RGEN $671M
FY22
KRYS $0.0M
RGEN $802M
FY23
KRYS $50.7M
RGEN $632M
FY24
KRYS $291M
RGEN $634M
FY25
KRYS $389M
RGEN $738M
KRYS
RGEN
Operating margin
FY16
KRYS —
RGEN 15.3%
FY17
KRYS —
RGEN 9.9%
FY18
KRYS —
RGEN 13.4%
FY19
KRYS —
RGEN 13.4%
FY20
KRYS —
RGEN 19.1%
FY21
KRYS —
RGEN 24.9%
FY22
KRYS —
RGEN 28.0%
FY23
KRYS −216.2%
RGEN 7.5%
FY24
KRYS 22.6%
RGEN −5.5%
FY25
KRYS 41.5%
RGEN 7.5%
KRYS
RGEN
Free cash flow
FY16
KRYS −$1.3M
RGEN $3.2M
FY17
KRYS −$4.1M
RGEN $12.0M
FY18
KRYS −$11.7M
RGEN $22.1M
FY19
KRYS −$25.1M
RGEN $48.7M
FY20
KRYS −$40.9M
RGEN $40.2M
FY21
KRYS −$116M
RGEN $51.9M
FY22
KRYS −$154M
RGEN $87.3M
FY23
KRYS −$101M
RGEN $77.7M
FY24
KRYS $119M
RGEN $150M
FY25
KRYS $189M
RGEN $93.9M
KRYS
RGEN
Return on capital
FY16
KRYS —
RGEN 15.2%
FY17
KRYS —
RGEN 4.3%
FY18
KRYS —
RGEN 3.9%
FY19
KRYS —
RGEN 4.6%
FY20
KRYS —
RGEN 7.7%
FY21
KRYS −61.2%
RGEN 11.4%
FY22
KRYS −76.9%
RGEN 12.4%
FY23
KRYS −47.7%
RGEN 1.7%
FY24
KRYS 20.7%
RGEN −1.6%
FY25
KRYS 43.6%
RGEN 2.4%
KRYS
RGEN
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.